INGNHealthcare · Medical Devices

INGN Stock Forecast: Inogen, Inc. Price Predictions for 2026-2027

Last close, 20 Nov 2026
$5.30
−2.21% on the day

The median 12-month analyst price target for Inogen, Inc. is $11. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 77 of 100 as at 21 Nov 2026 — inside the top quartile.

Market cap
$140.9M
Ticker Nerd rank
77/ 100
Median analyst target
$11
Analysts covering
2
Revenue$95.1M+3.0% y/y
Operating income−$5.1M
Net income−$3.9M
Free cash flow$1.0M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−6.9%
1M
−20.8%
YTD
−21.1%
1Y
−19.6%
From 52W high
−27.9%
From 52W low
+4.1%
$5.09
$7.35
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

One number for the whole business

Consensus tells you what everyone already believes. The model scores Inogen, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 21 Nov 2026
77/ 100

Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Accruals
87
Quality
85
Issuance
83
Volatility
74
Value
66
Momentum
48
Growth
39
Revisions
30

Accruals (87): Reported profit is backed by cash, and the company is not expanding recklessly.

Revisions (30): Analysts have, on balance, been cutting their forecasts.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

INGN stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on INGN, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$4.00$6.00$8.00$10.00$12.00Jan 26Apr 26Jul 26Oct 26INGNHigh $12Median $11Low $10

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says2 analysts
2
Buy
0
Hold
0
Sell
$10
Low
$11
Median
$12
High
Recent analyst actionsNewest first
DateFirmActionRatingTarget
7 Apr 2026Freedom BrokerInitiatesBuy$12
16 June 2025B. Riley SecuritiesInitiatesBuy—
22 May 2025NeedhamUpgradeBuy—
8 May 2025StifelMaintainsHold—
9 Apr 2025NeedhamReiteratesHold—
27 Feb 2025NeedhamReiteratesHold—
26 Feb 2025NeedhamReiteratesHold—
30 Jan 2025NeedhamReiteratesHold—
14 Jan 2025NeedhamReiteratesHold—
8 Nov 2024NeedhamReiteratesHold—
7 Aug 2024NeedhamReiteratesHold—
8 May 2024NeedhamReiteratesHold—
8 May 2024StifelMaintainsHold—
9 Apr 2024NeedhamReiteratesHold—
15 Feb 2024William BlairUpgradeOutperform—
8 Nov 2023JP MorganMaintainsUnderweight—
8 Aug 2023JP MorganDowngradeUnderweight—
8 Aug 2023StifelMaintainsHold—
14 July 2023NeedhamDowngradeHold—
20 Apr 2023NeedhamReiteratesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for INGN.

Market Radar

This page is one stock. Monday covers all of them.

INGN appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.

Free. Unsubscribe any time. Privacy

The AI build-out map
PDF
  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and servers

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

INGN vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 20 Nov 2026, Inogen, Inc. returned −19.6% against +6.9% for the S&P 500, dividends included.

INGN vs S&P 500, last 12 monthsTotal return, rebased to 100
8090100110120Jan 26Apr 26Jul 26Oct 26INGNS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

INGN analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingThis fiscal year
Analysts raising
0
Analysts cutting
1
Fundamentals

Financials

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
—
Price / sales
0.4×

Cheaper than 83% of US stocks

Price / book
0.9×

Cheaper than 74% of US stocks

EV / EBITDA
—
Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
45.5%

Higher than 56% of US stocks

Operating margin
−8.1%

Higher than 27% of US stocks

Net margin
−10.0%

Higher than 21% of US stocks

Returns & dividend
Return on equity
−19.8%

Higher than 32% of US stocks

Return on assets
−6.3%

Higher than 31% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.

Statistics

Key statistics

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Inogen, Inc. has a market value of $140.9M and an enterprise value of $59.0M.

  • Revenue in the twelve months to 30 June 2026: $354.3M. The latest quarter grew 3.0% year on year.

  • Net income over the same four quarters: −$24.6M, a −6.9% net margin.

  • Diluted earnings per share, trailing twelve months: −$0.90.

  • Free cash flow in the twelve months to 30 June 2026: −$9.7M.

  • Shares outstanding: 26.7M.

  • Inogen, Inc. employs 753 people — $471K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 20 Nov 2026

Data provided by Twelve Data

Peers

INGN and its peers

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelMedical Devices
CompanyMarket capTKN rank
INGNInogen, Inc.$140.9M77
MXCTMaxCyte, Inc.$146.8M94
TLSITriSalus Life Sciences, Inc.$138.8M34
RXSTRxSight, Inc.$185.0M54
LUNGPulmonx Corp.$111.9M87
ELMDElectromed, Inc.$191.7M89
QSIQuantum-Si, Inc.$199.7M49

Take a look at INGN’s peer groups, ranked by the model: healthcare stocks.

Look up any of the roughly 4,300 stocks we score.

The rank is the raw material. Whether the rules would actually own Inogen, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

FAQ

Questions about INGN

What is the INGN stock price forecast for 2026-2027?

The median 12-month analyst price target for Inogen, Inc. is $11, with estimates ranging from $9.5 to $12. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is INGN stock a buy right now?

Of the 2 analysts covering Inogen, Inc., 2 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Inogen, Inc. 77 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank INGN?

As at 21 Nov 2026, Inogen, Inc. ranks 77 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Accruals (87 of 100).

Will INGN stock go up?

No one can know that. What the data says: the median 12-month target from 2 analysts is $11, and Ticker Nerd's factor model ranks Inogen, Inc. 77 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the INGN stock forecast for 2030?

No analyst covering Inogen, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for INGN are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $9.5 to $12 over the next 12 months.

How has INGN stock performed over the past year?

Inogen, Inc. returned -19.6% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Inogen, Inc. do?

Inogen Inc. is a medical technology company focused on respiratory care for people living with chronic respiratory conditions. The company develops, manufactures, and markets portable oxygen concentrators for homecare use, helping patients receive supplemental long-term oxygen therapy in a more mobile form than traditional oxygen systems.

Company

About Inogen, Inc.

Inogen Inc. is a medical technology company focused on respiratory care for people living with chronic respiratory conditions. The company develops, manufactures, and markets portable oxygen concentrators for homecare use, helping patients receive supplemental long-term oxygen therapy in a more mobile form than traditional oxygen systems. Its product portfolio also includes stationary home oxygen concentrators, batteries, accessories, rental offerings, and airway-clearance solutions. Inogen serves patients through direct-to-consumer, business-to-business, and international channels, working with home medical equipment providers, prescribers, and distributors to broaden access to respiratory therapy products. Headquartered in Beverly, Massachusetts, Inogen plays a specialized role in the respiratory health market by addressing everyday oxygen therapy needs across home, travel, and other ambulatory settings.

CEO Mr. Andrew P. Reding · 753 employees · United States · https://www.provider.inogen.com